Related Experiment Video

Updated: Feb 26, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide

R R Khusnutdinov1, S V Boichuk2

  • 1Kazan State Medical University, Kazan, Republic of Tatarstan, Russia.

Bulletin of Experimental Biology and Medicine
|July 21, 2017
PubMed

Insights

Soft tissue sarcoma cell sensitivity to temozolomide involves complex mechanisms. Both O6-methylguanine-DNA-methyltransferase (MGMT) expression and oncosuppressor protein p53 activity influence treatment response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Temozolomide is an alkylating agent used in cancer therapy.
  • Sarcoma cell sensitivity to temozolomide is not fully understood.
  • O6-methylguanine-DNA-methyltransferase (MGMT) and p53 are key regulators in DNA repair and cell cycle control.

Purpose of the Study:

  • To investigate the mechanisms underlying soft tissue sarcoma cell sensitivity to temozolomide.
  • To explore the roles of MGMT expression and p53 activity in temozolomide response.

Main Methods:

  • Cell culture of human soft tissue sarcoma cell lines (A-673 and SK-LMS-1).
  • Treatment with the alkylating agent temozolomide.
  • Assessment of cell sensitivity, MGMT expression, and p53 activity.

Main Results:

  • A-673 Ewing's sarcoma cells demonstrated the highest sensitivity to temozolomide.
  • SK-LMS-1 leiomyosarcoma cells treated with temozolomide showed signs of cellular senescence.
  • Tumor cell sensitivity is influenced by a combination of MGMT levels and p53 activity.

Conclusions:

  • Soft tissue sarcoma sensitivity to temozolomide is multifactorial, involving MGMT and p53.
  • Different sarcoma subtypes may exhibit varying responses and resistance mechanisms.
  • Cellular senescence may be a response pathway in temozolomide-treated sarcoma cells.
Keywords:
MGMTagingapoptosisp53soft tissue sarcomas

More Related Videos

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

17.1K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K